首页> 外文期刊>Clinical & developmental immunology. >Autoimmune Cytopenias in Chronic Lymphocytic Leukemia
【24h】

Autoimmune Cytopenias in Chronic Lymphocytic Leukemia

机译:慢性淋巴细胞白血病中的自身免疫性Cytopenias

获取原文
           

摘要

The clinical course of chronic lymphocytic leukemia (CLL) may be complicated at any time by autoimmune phenomena.The most common ones are hematologic disorders, such as autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP). Pure red cell aplasia (PRCA) and autoimmune agranulocytosis (AG) are, indeed, more rarely seen. However, they are probably underestimated due to the possible misleading presence of cytopenias secondary to leukemic bone marrow involvement or to chemotherapy cytotoxicity. The source of autoantibodies is still uncertain, despite the most convincing data are in favor of the involvement of resting normal B-cells. In general, excluding the specific treatment of underlying CLL, the managementof these complications is not different from that of idiopathic autoimmune cytopenias or of those associated to other causes. Among different therapeutic approaches, monoclonal antibody rituximab, given alone or in combination, has shown to be very effective.
机译:自身免疫现象可随时使慢性淋巴细胞性白血病(CLL)的临床过程复杂化,最常见的是血液系统疾病,例如自身免疫性溶血性贫血(AIHA)和免疫性血小板减少症(ITP)。实际上,纯红细胞发育不全(PRCA)和自身免疫性粒细胞缺乏症(AG)很少见。但是,由于白血病继发于白血病骨髓或化疗引起的细胞毒性,可能会导致误导性的血细胞减少,因此可能低估了它们的存在。尽管最具说服力的数据支持静息正常B细胞​​的参与,但自身抗体的来源仍不确定。通常,除了对潜在CLL的特异性治疗外,这些并发症的处理与特发性自身免疫性血细胞减少症或与其他原因相关的那些没有区别。在不同的治疗方法中,单独或联合给予利妥昔单抗单克隆抗体已显示非常有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号